Zacks Investment Research upgraded shares of Myomo (NYSEAMERICAN:MYO) from a hold rating to a buy rating in a report issued on Friday morning, Zacks.com reports. The firm currently has $0.75 target price on the stock.
According to Zacks, “Myomo, Inc. is a commercial stage medical robotics company. It offers expanded mobility which suffering from neurological disorders and upper limb paralysis. The company develops and markets the MyoPro(R) product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals. Myomo, Inc. is headquartered in Cambridge,Massachusetts. “
Separately, Ascendiant Capital Markets began coverage on Myomo in a report on Tuesday, July 30th. They issued a buy rating and a $2.00 price target on the stock.
Myomo (NYSEAMERICAN:MYO) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.02. The business had revenue of $0.88 million during the quarter, compared to analysts’ expectations of $1.09 million.
A hedge fund recently raised its stake in Myomo stock. Bank of New York Mellon Corp increased its position in Myomo Inc (NYSEAMERICAN:MYO) by 87.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,925 shares of the company’s stock after purchasing an additional 21,925 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.38% of Myomo worth $68,000 as of its most recent SEC filing.
Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis used for the purpose of supporting a patient's weak or deformed arm to enable and improve functional activities of daily living, ADLs, in the home and community.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.